Ventilator-associated pneumonia--the wrong quality measure for benchmarking, Ann Intern Med, vol.147, issue.11, pp.803-808, 2007. ,
Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study, Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol, vol.36, issue.11, pp.1999-2006, 2017. ,
A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria, Crit Care Med, vol.40, issue.1, pp.281-285, 2012. ,
Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients, Ann Intern Med, vol.129, issue.6, pp.433-473, 1998. ,
Relative risk and population-attributable fraction of ICU death caused by susceptible and resistant Pseudomonas aeruginosa ventilator-associated pneumonia: a competing risks approach to investigate the OUTCOMEREA database, Crit Care [Internet], vol.19, issue.1, 2015. ,
,
, Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies, Lancet Infect Dis, vol.13, issue.8, pp.665-71, 2013.
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.63, issue.5, pp.61-111, 2016. ,
Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.18, issue.3, pp.268-81, 2012. ,
Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med, vol.157, pp.912-918, 1998. ,
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospitalacquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT), Eur Respir J, vol.50, issue.3, 2017. ,
Epidemiology and outcomes of ventilator-associated pneumonia in a large US database, Chest, vol.122, issue.6, pp.2115-2136, 2002. ,
Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia, Intensive Care Med, vol.20, issue.3, pp.193-201, 1994. ,
Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis, Am J Respir Crit Care Med, vol.184, issue.10, pp.1133-1142, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00841199
Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models, Intensive Care Med, vol.36, issue.5, pp.781-790, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00465413
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group, Intensive Care Med, vol.22, issue.5, pp.387-94, 1996. ,
Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality, Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol, vol.32, issue.3, pp.413-433, 2013. ,
Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients, Intensive Care Med, vol.39, issue.4, pp.682-92, 2013. ,
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia, Antimicrob Agents Chemother, vol.58, issue.3, pp.1372-80, 2014. ,
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact, Antimicrob Agents Chemother, vol.50, issue.1, pp.43-51, 2006. ,
Methods to determine fitness in bacteria, Methods Mol Biol Clifton NJ, vol.642, pp.113-134, 2010. ,
Mutation of nfxB causes global changes in the physiology and metabolism of Pseudomonas aeruginosa, J Proteome Res, vol.9, issue.6, pp.2957-67, 2010. ,
Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates, Antimicrob Agents Chemother, vol.60, issue.3, pp.1767-78, 2016. ,
Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks, Environ Microbiol, vol.14, issue.8, pp.1968-81, 2012. ,
Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps, vol.8, 201725. ,